Bioprocess reproducibility starts before the reactor

NIST published an integrated cell-culture and fed-batch bioreactor protocol on 24 September 2026 for its standardised Chinese hamster ovary cell platform. Such cells are widely used as a manufacturing platform for recombinant monoclonal antibodies. The publication is intended to help laboratories generate material with controlled and documented process histories.

The workflow begins before the main bioreactor. It covers recovery of cryopreserved cells, automated measurement of cell concentration and viability, preparation of chemically defined feed media, seed-train expansion and fed-batch cultivation in a single-use stirred tank. It also defines operating conditions for temperature, agitation, dissolved oxygen, pH, feeding, glucose supplementation, antifoam addition, sampling, harvest and initial clarification.

Dunes Bureau interpretation: the useful unit of control is the whole upstream process, not an isolated reactor recipe. If two sites match temperature and pH during production but handle thawing, seed expansion or feed preparation differently, their material may not carry the same process history. A technology-transfer package should therefore map inputs, checks, timing and decision points from the frozen vial to harvest.

For managers, this changes the handover question. Instead of asking whether another site owns comparable equipment, ask whether it can reproduce the sequence, measurements and intervention rules that produce a comparable batch. Single-use hardware can reduce cleaning and changeover work, but it does not replace disciplined control of media, sensors, sampling and operator actions.

The NIST publication supplies a reference workflow and a representative 14-day profile; it does not establish commercial yield, product approval or economics for a particular manufacturer. Companies would still need product-specific development, validation and quality oversight before adopting any protocol in regulated production.